Literature DB >> 10067974

Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.

C H Kon1, N L Occleston, G W Aylward, P T Khaw.   

Abstract

PURPOSE: Proliferative vitreoretinopathy (PVR) is a major cause of failure of retinal detachment surgery. It is believed to be a wound-healing process in the retina. Many of the cellular functions are influenced by cytokines and growth factors such as interleukins (ILs). The present study was conducted to investigate the presence of transforming growth factor-beta 2 (TGF-beta2), basic fibroblast growth factor (bFGF), IL-1beta, IL-6, and protein in the vitreous of patients with retinal detachment and to determine the value of these mediators in predicting the future development of PVR.
METHODS: A prospective study was conducted in 140 consecutive patients with rhegmatogenous retinal detachment in whom vitrectomy was considered necessary. Vitreous samples were analyzed for the presence of TGF-beta2, bFGF, IL-1beta, IL-6, and protein. Patients were then followed up for 3 months for the development of postoperative PVR.
RESULTS: The mean levels of TGF-beta2, bFGF, IL-1beta, and protein in the vitreous were significantly higher (P < 0.05) in patients with preoperative PVR compared with those without. The mean levels of TGF-beta2, bFGF, IL-6, and protein in the vitreous were significantly higher (P < 0.05) in patients who had postoperative PVR compared with those who did not. Multivariate logistic regression analysis showed IL-6 and protein to be significant (P < 0.05), independent, predictive risk factors for the development of PVR.
CONCLUSIONS: The various cytokines may play a role in the pathobiology of PVR. High vitreous levels of IL-6 and protein were identified as significant risk factors for PVR. A model was developed to predict the probability of development of postoperative PVR in these patients, and it may be used to indicate intravitreal pharmacologic treatment for those at risk.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067974

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Inhibitory effect of certain neuropeptides on the proliferation of human retinal pigment epithelial cells.

Authors:  J Troger; S Sellemond; G Kieselbach; M Kralinger; E Schmid; B Teuchner; Q A Nguyen; E Schretter-Irschick; W Göttinger
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

Review 3.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

4.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

5.  Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid.

Authors:  R H Y Asaria; C H Kon; C Bunce; C S Sethi; G A Limb; P T Khaw; G W Aylward; D G Charteris
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

6.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

7.  Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.

Authors:  H Funatsu; H Yamashita; H Noma; T Mimura; K Sakata; S Hori
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

8.  Role of HGF/c-Met in serum-starved ARPE-19 cells.

Authors:  Eun Jung Jun; Hwa Sun Kim; Yeong Hoon Kim
Journal:  Korean J Ophthalmol       Date:  2007-12

9.  Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.

Authors:  Barbara Cvenkel; Andreja Natasa Kopitar; Alojz Ihan
Journal:  Mediators Inflamm       Date:  2010-05-05       Impact factor: 4.711

10.  The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration.

Authors:  Anna Tsapara; Phillip Luthert; John Greenwood; Caroline S Hill; Karl Matter; Maria S Balda
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.